Compare EVAX & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | VNRX |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.7M | 38.2M |
| IPO Year | 2021 | N/A |
| Metric | EVAX | VNRX |
|---|---|---|
| Price | $5.21 | $0.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $12.33 | $2.50 |
| AVG Volume (30 Days) | 89.1K | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,650,000.00 | $1,472,007.00 |
| Revenue This Year | $128.77 | $55.98 |
| Revenue Next Year | N/A | $420.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 132.17 | 14.48 |
| 52 Week Low | $1.20 | $0.22 |
| 52 Week High | $12.15 | $0.94 |
| Indicator | EVAX | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 60.46 |
| Support Level | $4.56 | $0.22 |
| Resistance Level | $5.48 | $0.39 |
| Average True Range (ATR) | 0.43 | 0.02 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 41.18 | 68.05 |
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.